Janus Henderson Group PLC Purchases 679,124 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Janus Henderson Group PLC grew its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 63.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,746,320 shares of the company's stock after acquiring an additional 679,124 shares during the period. Janus Henderson Group PLC owned 3.45% of Tyra Biosciences worth $24,291,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in Tyra Biosciences in the 4th quarter worth $31,000. US Bancorp DE purchased a new stake in Tyra Biosciences in the fourth quarter worth about $50,000. BNP Paribas Financial Markets bought a new position in shares of Tyra Biosciences in the fourth quarter worth about $60,000. Aquatic Capital Management LLC purchased a new position in shares of Tyra Biosciences during the 4th quarter valued at about $64,000. Finally, Wells Fargo & Company MN grew its stake in shares of Tyra Biosciences by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after acquiring an additional 3,236 shares during the period. Hedge funds and other institutional investors own 84.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Finally, Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday. They issued an "overweight" rating and a $33.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Price Performance

Shares of TYRA stock traded down $0.10 during mid-day trading on Wednesday, hitting $9.88. The company had a trading volume of 38,135 shares, compared to its average volume of 261,204. The stock's 50 day moving average price is $9.52 and its 200-day moving average price is $12.74. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The company has a market capitalization of $524.32 million, a P/E ratio of -6.14 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.